Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...

Edwards said study data supporting earlier use of its Sapien heart valves to treat patients who have severe aortic stenosis without symptoms is changing clinical practice and helping to accelerate ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 7 years, there was no difference in clinical outcomes ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...